Recent studies on GC have demonstrated the benefit of combining ICIs with other targeted agents, such as trastuzumab (HER2 inhibitor) and ramucirumab (VEGFR2 inhibitor)4, 5, 24; combining ICIs with other targeted agents might also be promising, especially if there is a correlation between CPS and the target biomarker. Here, KDR is linked to gastric cancer.